QuidelOrtho announces the appointment of Jonathan Siegrist, PhD, as its new Executive Vice President of Research and Development R&D and Chief Technology Officer CTO , effective as of October 7. Siegrist brings a wealth of industry expertise and leadership experience with over 15 years in molecular diagnostics, microfluidic platforms, and biomedical engineering. He most recently was the CTO and Head of Assay Research and Development at Cepheid. Prior to Cepheid, he co-founded a diagnostics manufacturing company. Reporting to Brian Blaser, President and Chief Executive Officer, Siegrist will spearhead QuidelOrtho’s R&D strategy with a focus on menu expansion and advancing critical platforms. His leadership is expected to advance QuidelOrtho’s industry-leading expertise in immunoassay and molecular testing and award-winning solutions in clinical labs and transfusion medicine. Werner Kroll, Senior Vice President, R&D, will support a smooth leadership transition and related activities until his retirement in March 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QDEL:
- Five Below downgraded, DoorDash upgraded: Wall Street’s top analyst calls
- QuidelOrtho assumed with Neutral from Sell at UBS
- QuidelOrtho appoints Lee Bowman as chief human resources officer
- Verizon making $20B fiber buy, Topgolf and Fortive splitting up: Morning Buzz
- Craig-Hallum ups QuidelOrtho to Buy on untapped earnings power